BREAKING NEWS: Biolex Therapeutics Announces Completion of Enrollment in SELECT-2 Phase 2B Trial of Locteron® in Chronic Hepatitis C
Biolex Therapeutics Researchers Present Locteron® U.S. Phase 2a Hepatitis C Trial Results at EASL Conference
